Investors Overview

For Investor Relations Please Contact us

info@ventripoint.com
(416) 848-4156

Projected Market Growth of 66% Over Seven Years

Ventripoint Diagnostics Ltd. is a medical device company engaged in the development and commercialization of enhanced ultrasound technologies. It sells its products worldwide

The Next Evolution of Whole-Heart Imaging

A New Tool for Managing and Monitoring Cardiovascular Disease

Heart disease is the leading cause of death for both men and women worldwide. Presently, there is an acute need for fast, affordable, and highly accurate 3D visualization of the heart to provide better early diagnosis and treatment.

Pioneers in AI for Whole-Heart Imaging
Ventripoint’s patented, FDA cleared VMS+ technology is the first and only cost-effective diagnostic tool to measure the volume and function of all four chambers of the heart. It is uniquely able to evaluate the heart’s right ventricle, which is particularly difficult to image and analyze with conventional ultrasound.

VMS+ connects to standard ultrasound machines, the world’s most widely used cardiac imaging technology. The system generates 3D images of the heart with accuracy equivalent to the more time-consuming and expensive MRI, the current gold standard for heart imaging.

Fast, Reliable Whole-Heart Imaging

A New Tool for Managing and Monitoring Cardiovascular Disease
Heart disease is the leading cause of death for both men and women worldwide. Presently, there is an acute need for fast, affordable, and highly accurate 3D visualization of the heart to provide better early diagnosis and treatment.

Pioneers in AI for Whole-Heart Imaging
Ventripoint’s patented, FDA cleared VMS+ technology is the first and only cost-effective diagnostic tool to measure the volume and function of all four chambers of the heart. It is uniquely able to evaluate the heart’s right ventricle, which is particularly difficult to image and analyze with conventional ultrasound.

VMS+ connects to standard ultrasound machines, the world’s most widely used cardiac imaging technology. The system generates 3D images of the heart with accuracy equivalent to the more time-consuming and expensive MRI, the current gold standard for heart imaging.

The global ultrasound equipment market is projective to grow from $7.8 billion in 2021 to $12.9 billion in 2028.